* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Novo Nordisk A/S stock dips after 2025 guidance cut. However, click for why NVO's strong GLP-1 prospects, growing pipeline, ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

A new analysis of 11 global studies shows that people tend to regain lost weight after stopping anti-obesity medications like ...

People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

Obesity is not a personal moral failing. It is a complex, multi-factorial condition driven by genetics, environment, and a ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...